No Data
No Data
瑛泰醫療:二零二三年年報
Shanghai INT Medical Instruments Submits Application to Shanghai Regulatory Bureau for A Share Listing
Shanghai INT Medical Instruments Submits Application to Shanghai Regulatory Bureau for A Share Listing
Yingtai Healthcare (01501.HK): Submission of listing guidance and filing application materials to the Shanghai Regulatory Bureau of the China Securities Regulatory Commission
Gelonghui, April 7, 丨 Yingtai Medical (01501.HK) announced that on April 7, 2024, the company submitted listing guidance and filing application materials to the Shanghai Regulatory Bureau of the China Securities Regulatory Commission. Due to business development needs, the company plans to prepare for listing on stock exchanges in China (“Recommended A-share listing”). The advising agency for A-share listing is China International Finance Co., Ltd. The proposed A-share listing is still in the early planning stage. As of the announcement date, the company has not submitted any formal listing application to any relevant regulatory authority in China.
J.P. Morgan sold 5.288 million H shares of Yingtai Healthcare (01501.HK), worth approximately HK$144 million
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, JPMorgan Chase & Co. (JPMorgan Chase & Co.) sold $5288 million H-shares worth about HK$144 million on April 2 at an average price of HK$27.275 per share on the market and HK$27.24 per share outside the market. After the sale, J.P. Morgan Chase's latest shareholding was 1.374,900 shares, and the good position ratio dropped from 6.39% to 1.31%. Additional Information: JP Morgan Chase & Co. ce
Yingtai Healthcare (01501.HK): Issuance of 5 million bonus shares in accordance with the share incentive plan
Gelonghui, April 2, 丨 Yingtai Medical (01501.HK) announced that 5 million bonus shares will be allocated and issued on March 29, 2024 in accordance with the share incentive plan.
INT MEDICAL(1501.HK):SOLID EARNINGS AMID CHALLENGING BUSINESS ENVIRONMENT
INT Medical unveiled its 2023 results, with revenue up 28.5% YoY to RMB753mn, 11
No Data